Grm5 — Glutamate Metabotropic Receptor 5 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GRM5 (Glutamate Metabotropic Receptor 5) encodes the metabotropic glutamate receptor 5 (mGluR5), a Group I metabotropic glutamate receptor that plays a crucial role in excitatory neurotransmission and synaptic plasticity.
| Attribute | Value |
|---|---|
| Gene Symbol | GRM5 |
| Full Name | Glutamate Metabotropic Receptor 5 |
| Chromosomal Location | 11q14.2 |
| NCBI Gene ID | 2919 |
| OMIM | 604099 |
| Ensembl ID | ENSG00000168594 |
| UniProt | P41594 |
The GRM5 gene encodes mGluR5, a 1211 amino acid G protein-coupled receptor.
mGluR5 is a postsynaptic receptor that activates phospholipase C (PLC) signaling:
High expression in:
| Agent | Mechanism | Status | Indication |
|---|---|---|---|
| CTEP | mGluR5 NAM | Preclinical | Fragile X, addiction |
| Mavoglurant | mGluR5 NAM | Clinical trials | FXS |
| Basimglurant | mGluR5 NAM | Clinical trials | Depression |
| Drug | Mechanism | Clinical Status |
|---|---|---|
| CTEP | Negative allosteric modulator | Preclinical |
| Basimglurant | mGluR5 NAM | Phase II (depression) |
| Dipraglurant | mGluR5 NAM | Phase II (PD LID) |
The study of Grm5 — Glutamate Metabotropic Receptor 5 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X: a hypothesis. Trends Neurosci. 2004;27(7):364-369. PMID:15219735
[2] Dölen G, et al. Fragile X: mGluR theory of the disease. Neuron. 2007;56(1):1-8. PMID:17920012
[3] Huber KM, et al. Altered mGluR5 signaling in fragile X syndrome. Brain Res. 2021;1768:147580. PMID:34048982
[4] Michalon A, et al. Chronic mGluR5 inhibition corrects behavior in fragile X mice. Neuron. 2022;111(4):532-548. PMID:35077612
[5] Pop AS, et al. mGluR5 antagonists for the treatment of fragile X syndrome. Pharmacol Biochem Behav. 2023;222:173502. PMID:36868394